Shots:

• Dermira to receive $50M as an option exercise fee- $30M milestone with the initiation of P-III studies- $85M as the regulatory & commercial milestone and royalties on sales. Almirall to get development & commercialization rights of lebrikizumab for atopic dermatitis & other indications in Europe
• In Feb’19- Almirall and Dermira entered into an option and license agreement and exercise of the option follows P-IIb study results which demonstrated in meeting its 1EPs and a dose-dependent improvement in patients with moderate-to-severe atopic dermatitis
• Lebrikizumab is mAb- binds with IL-13 to prevent the formation of the IL-13Rα1/IL-4Rα heterodimer complex thereby inhibiting the biological effects of IL-13 with its expected initiation of P-III study in H2’19

Click here to read full press release/ article | Ref: Almirall | Image: Investor Place